The 5' regulatory sequence of the PMP22 in the patients with Charcot-Marie-Tooth disease

• Autorzy: Sinkiewicz-Darol E. , Kabzinska D. , Moszynska I. , Kochanski A.
• Języki publikacji: EN

Abstrakty

EN

Little is known about the molecular background of clinical variability of Charcot-Marie-Tooth type 1A (CMT1A) disease and hereditary neuropathy with liability to pressure palsies (HNPP). The CMT1A and HNPP disorders result from duplication and deletion of the PMP22 gene respectively. In a series of studies performed on affected animal transgenic models of CMT1A disease, expression of the PMP22 gene (gene dosage) was shown to correlete with severity of CMT course (gene dosage effect). In this study we hypothesized that single nucleotide polymorphisms (SNPs) located within the 5' regulatory sequence of PMP22 gene may be responsible for the CMT1A/HNPP clinical variability. We have sequenced the PMP22 5' upstream regulatory sequence in a group of 45 CMT1A/HNPP patients harboring the PMP22 duplication (37) /deletion (8). We have identified five SNPs in the regulatory sequence of the PMP22 gene. Three of them i.e. -819C>T, -4785G>T, -4800C>T were detected both in the patients and in the control group. Thus, their pathogenic role in the regulation of the expression of the PMP22 gene seems not to be significant. Two SNPs i.e. -4210T>C and -4759T>A were found only in the CMT patients. Their role in the regulation of the PMP22 gene expression can not be excluded. Additionally we have detected the Thr118Met variant in exon 4 of the PMP22 gene, which was previously reported by other authors, in one patient. We conclude that the 5' regulatory sequence of the PMP22 gene is conserved at the nucleotiode level, however rarely occurring SNPs variant in the PMP22 regulatory sequence may be associated with the gene dosage effect.

Słowa kluczowe

EN

human disease; PMP22 gene; patient; Charcot-Marie-Tooth disease; Charcot-Marie-Tooth type 1A disease; hereditary neuropathy; gene expression

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2010
• Tom: 57
• Numer: 3
• Opis fizyczny: p.373-377,fig.,ref.

Twórcy

autor

Sinkiewicz-Darol E.

• Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Kabzinska D.

autor

Moszynska I.

autor

Kochanski A.

Bibliografia

• Aarskog NK, Vedeler CA (2000) Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107: 494-498. 
• Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U (1995) Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 11: 274-280. 
• De Jonghe PJL (1998) The inherited neuropathies of the peripheral nervous system in the DNA era: genotype-phenotype correlations. PhD Thesis, University of Antwerp.
• Hai M, Bidichandani SI, Patel PI (2001) Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. J Neurosci Res 65: 508-519.  
• Itou J, Suyama M, Imamura Y, Deguchi T, Fujimori K, Yuba S, Kawarabayasi Y, Kawasaki T (2009) Functional and comparative genomics analyses of pmp22 in medaka fish. BMC Neuroscience 10: 60. 
• Li J, Bai Y, Ghandour K, Qin P, Grandis M, Trostinskaia A, Ianakova E, Wu X, Schenone A, Vallat JM, Kupsky WJ, Hatfield J, Shy ME (2005) Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 128: 1168-1177. 
• Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI (1991) DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66: 219-232. 
• Maier M, Castagner F, Berger P, Suter U (2003) Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons. Mol Cell Neurosci 24: 803-817. 
• Manfioletti G, Ruaro ME, Del Sal G, Philipson L, Schneider C (1990) A growth arrest-specific (gas) gene codes for a membrane protein. Mol Cell Biol 10: 2924-2930. 
• Nelis E, De Jonghe P, De Vriendt E, Patel PI, Martin JJ, Van Broeckhoven C (1998) Mutation analysis of the nerve specific promoter of the peripheral myelin protein 22 gene in CMT1 disease and HNPP. J Med Genet 35: 590-593. 
• Numakura C, Lin C, Tohru Ikegami T, Guldberg P, Hayasaka K (2002) Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. Human Mutat 20: 392-398. 
• Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, Barker DF, Martin JJ, De Visser M, Bolhuis PA et al. (1991) Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromusc Disord 1: 93-97. 
• Saberan-Djoneidi D, Sanguedolce V, Assouline Z, Levy N, Passage E, Fontes M (2000) Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 248: 223-231. 
• Sereda M, Griffiths I, Pühlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA (1996) A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16: 1049-1060. 
• Skre H (1974) Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6: 98-118. 
• Snipes GJ, Suter U, Welcher AA, Shooter EM (1992) Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 117: 225-238. 
• Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI (1994) Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 269: 25795-25808. 
• Van de Wetering RAC, Gabreels-Festen A, Kremer H, Kalscheuer VM, Gabreels F, Mariman EC (1999) Regulation and expression of the murine Pmp22 gene. Mamm Genome 10: 419-422